A phase II study of Recchia's immunomodulatory schedule (RIS) as a maintenance therapy in high-risk tumors after a response.
Manuel Sureda
No relevant relationships to disclose
Joseba Rebollo
No relevant relationships to disclose
Begona Vazquez
No relevant relationships to disclose
Pere Bretcha
No relevant relationships to disclose
Rosa CaƱon
No relevant relationships to disclose
Maritza Duarte
No relevant relationships to disclose
Vicente Munoz
No relevant relationships to disclose
Antonio Brugarolas
No relevant relationships to disclose